Filing summary: Hillstream BioPharma, Inc. — Form 10-Q, quarter ended March 31, 2023
Entity discrepancy: The request identifies Canton Strategic Holdings, Inc., but the supplied filing is for Hillstream BioPharma, Inc. (Nasdaq: HILS). The summary below reflects the supplied filing.
Business context and reporting period
Hillstream is a preclinical biotechnology company developing cancer therapies, including HSB-1216, its most advanced candidate, and the immuno-oncology candidates HSB-3215 and HSB-1940. The unaudited results cover the three months ended March 31, 2023, with comparison to the three months ended March 31, 2022. The company reported no revenue in either period.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $1.05 million | $0.31 million |
| General and administrative expense | $1.67 million | $1.04 million |
| Total operating expenses | $2.71 million | $1.35 million |
| Net loss | $2.69 million | $2.94 million |
| Basic and diluted loss per share | $0.23 | $0.28 |
| Cash used in operating activities | $3.46 million | $2.73 million |
| Cash and cash equivalents, March 31 | $3.57 million | $6.51 million at December 31, 2022 |
| Total current liabilities, March 31 | $1.52 million | $1.14 million at December 31, 2022 |
There are no revenue-based margins to assess. The company had $4.72 million in current assets, no reported noncurrent assets, and $3.20 million in stockholders’ equity at March 31. Current liabilities included a $559,917 insurance-premium financing liability due in October 2023; the filing reports no other outstanding debt balance at quarter-end. Cash flow from financing activities was $523,364, primarily from insurance-premium financing, partly offset by repayments and offering costs.
Material changes versus the prior comparable period
- R&D expense rose $739,848, or 240%, primarily due to increased preclinical activity, R&D stock compensation, and consulting costs.
- G&A expense increased $623,390, or 60%, mainly reflecting investor-relations costs, stock-based compensation, and legal expenses.
- Despite higher operating costs, net loss narrowed by $254,116. The comparison is affected by a $1.59 million debt-discount-related interest charge in Q1 2022, largely arising when related-party convertible notes converted in connection with the IPO.
- Operating cash use increased by approximately $736,000, and cash declined by $2.94 million during Q1 2023.
Outlook, risks, contingencies, and unusual items
- Management aims to submit an IND for HSB-1216 and begin a clinical study in late 2023 or early 2024; any clinical data from a study initiated in 2024 was anticipated in 2025. These are plans, not assurances. The company also intends to submit an IND for HSB-3215 to support possible clinical studies in 2025.
- The filing states that recurring operating losses and negative cash flows, together with available resources and plans, raise substantial doubt about the company’s ability to continue as a going concern for at least one year after issuance of the financial statements. Management says substantial additional funding is needed; financing may not be available on acceptable terms or in time.
- On May 2, 2023, after quarter-end, the company closed an offering of 5.3 million shares at $0.50 per share, for approximately $2.2 million in net proceeds, assuming no over-allotment exercise. It granted a 45-day option for up to 795,000 additional shares and issued underwriter representative warrants tied to securities sold.
- The company’s option to license ABSI HER2/HER3 technology expires September 30, 2023 unless extended. The Minotaur/Taurus arrangements for HSB-1940 include a $150,000 upfront payment, research funding, development and regulatory milestones, and royalties or sales-based payments.
- Potential payments under a small-molecule asset purchase agreement include a $50,000 initial payment subject to a funding condition and up to approximately $1.75 million in clinical and sales milestones. The filing says the funding condition had not been met; it also reports the $50,000 in accounts payable.
- Management concluded disclosure controls and procedures were not effective at March 31, 2023, citing material weaknesses in segregation of duties and technical accounting review expertise. Remediation efforts include contract reviews and use of third-party accounting experts.
- The filing reports no material legal proceedings known to the company and no material changes to the risk factors disclosed in its 2022 Form 10-K. It notes COVID-19 previously delayed the start of IND-enabling studies by more than a year and could continue to affect development timelines.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing is Hillstream BioPharma, not Canton Strategic Holdings.
- Assess cash runway and financing needs, including the effect of the May 2023 offering and subsequent cash burn.
- Track HSB-1216 IND-enabling work and FDA submission timing, as well as the status and funding of other pipeline programs.
- Review dilution from the May offering, underwriter option and warrants, outstanding options, and other potential securities.
- Monitor remediation of the disclosed internal-control material weaknesses and the September 2023 ABSI option deadline.
- Note that the MD&A narrative once describes Q1 2023 operating cash use as approximately $2.9 million, while the cash-flow statement and another MD&A passage report $3.46 million; verify the reported figure against the filed financial statements.